#	Pagina
attuale pagina	/open-h2020/projects/221067/index.html

Opendata, web and dolomites

HAIKU

A breakthrough alternative to antibiotics for preventing and curing infectious diseases at Intensive Care Units

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

HAIKU project word cloud

Explore the words cloud of the HAIKU project. It provides you a very rough idea of what is the project "HAIKU" about.

healthcare therapies medicines discount bacteria beds gram risked removing 150 275 15 56 generating complete 800 finalise curing 13 de companies morbidity 14 6 01 intensive stays infections inhibitory prolonged price diseases antimicrobial days patients newly group families resistance preventing created removal care resistant protection 240 1000 therapy sales public consist multiple hospital develops clinical company critical pharma licensed amr 23 natural net infectivity private infectious market reduce remab icu benefit irr 21 antibodies risk 10 mortality first competitors addressable treatment social curative ra gt biotech negative million 2026 class icus rate portfolio jobs worldwide therapeutics line royalties drug acquired freeing admitted preventive lives share trials total ebitda cumulative ph2 mission antibiotics units molecule

Project "HAIKU" data sheet

The following table provides information about the project.

Coordinator	REMAB THERAPEUTICS SL Organization address address: C FEIXA LLARGA SN EDIFICIO BIOPOL OFFICE 3 city: HOSPITALET DE LLOBREGAT postcode: 8907 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	https://remabtx.com/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2018
Duration (year-month-day)	from 2018-12-01 to 2019-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	REMAB THERAPEUTICS SL REMAB THERAPEUTICS SL Organization address address: C FEIXA LLARGA SN EDIFICIO BIOPOL OFFICE 3 city: HOSPITALET DE LLOBREGAT postcode: 8907 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (HOSPITALET DE LLOBREGAT)	coordinator	50˙000.00

Map

Project objective

Hospital-acquired infections are a major cause of morbidity, mortality and costs in Intensive care units (ICUs) worldwide. The most critical infectious group consist of Gram-negative bacteria that are resistant to multiple antibiotics.

We have developed RA-01, a novel drug product and a first line therapy for preventing and curing infectious diseases at ICUs based on the removal of inhibitory antibodies, which are used by bacteria to facilitate their infectivity. This new drug allows an immediate protection to patients admitted to ICU without generating antimicrobial resistance (AMR).

RA-01 will reduce public/private healthcare systems costs and improve a social benefit by freeing up hospital beds: €9,150 reduction in treatment costs, 7 days less at ICU and €15 k reduction in ICU costs.

Currently, our competitors are focused on new antibiotics and antibodies, so there are no other companies working in the removing of specific antibodies as a preventive and curative method for infectious diseases. The total potential market is estimated to be >13 million patients/year. From this market, will be target ICU patients at risk for prolonged stays: >4 million patients.

RemAb Therapeutics is a biotech company that develops a novel class of medicines by removing natural specific antibodies. Our mission is to advance our portfolio of therapies to clinical trials and improve the lives of patients and families affected by infectious diseases. Our drug molecule will be developed and de-risked through clinical trials-Ph2 and then licensed to pharma companies, to finalise their development and bring them to the market

By 2026 we expect to reach: a) 14% royalties’ rate on net sales with a RA-01 price to healthcare systems of €800-1000 (complete treatment); b) Total addressable market growing up to about €275 m; c) Net present value of €21.4 m (10% discount rate) and an IRR of 56%; d) Cumulative EBITDA over €23 m; e) 6% market share (240,000 patients); f) 15 newly created jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HAIKU" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HAIKU" are provided by the European Opendata Portal: CORDIS opendata.